Suchergebnisse - "Cervantes, A"

PubPharm (4)

1

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

enthalten in: Scientific reports | 2019

von Borrero-Palacios, A. | Cebrián, A. | Gómez Del Pulgar, M. | +21

ErratumIn: Sci Rep. 2019 May 17;9(1):7706. - PMID 31097738

2

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

enthalten in: British journal of cancer | 2016

von Elez, E. | Hendlisz, A. | Delaunoit, T. | +6

3

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Sclafani, F. | Chau, I. | Cunningham, D. | +16

4

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

enthalten in: British journal of cancer | 2015

von Macarulla, T. | Cervantes, A. | Tabernero, J. | +10

1
[1]